<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3417">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582201</url>
  </required_header>
  <id_info>
    <org_study_id>C-1300-01</org_study_id>
    <nct_id>NCT04582201</nct_id>
  </id_info>
  <brief_title>An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.</brief_title>
  <official_title>A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AgenTus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agenus Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Study of AGENT-797 to treat moderate to severe acute respiratory syndrome in&#xD;
      COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study to evaluate the safety and efficacy of agenT-797, an unmodified,&#xD;
      allogeneic iNKT therapy, in patients with coronavirus disease 2019 (COVID-19), requiring&#xD;
      mechanical ventilation, and with moderate to severe ARDS as determined by the Berlin&#xD;
      definition.&#xD;
&#xD;
      The study will be conducted in 2 parts. Part 1 will employ a standard 3+3 dose escalation&#xD;
      design of agenT-797. All patients will receive a single infusion of agent-797. Patients will&#xD;
      also receive other treatments and supportive care per discretion of the Principal&#xD;
      Investigator. Once the maximum tolerated dose of agenT-797 has been cleared in Part 1, Part 2&#xD;
      of the study will be opened and enroll eligible patients in the Expansion Cohort.&#xD;
&#xD;
      Details of the analyses will be described in a statistical analysis plan.&#xD;
&#xD;
      A Safety Monitoring Committee will be established to assess safety and decide on escalation&#xD;
      to next Cohort and expansion dose, as well as any protocol modification to include less&#xD;
      severe cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number and severity of adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities</measure>
    <time_frame>6 months</time_frame>
    <description>Number of Dose Limiting Toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess time to improvement in pulmonary function.</measure>
    <time_frame>30 days</time_frame>
    <description>Time to extubation.&#xD;
Assessment of ventilator-free days.&#xD;
Oxygenation improvement as per Berlin definition (ARDS 2012).&#xD;
Supportive interventions used (e.g. use of prone ventilation, paralytics, pulmonary vasodilators, and other interventions affecting oxygenation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of virus detected in respiratory tract samples.</measure>
    <time_frame>30 days</time_frame>
    <description>Decay in quantitative viral burden from upper and lower respiratory tract samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess longevity of agenT-797 infusion.</measure>
    <time_frame>30 days</time_frame>
    <description>Persistence of allogeneic invariant natural killer T cells (iNKT) non-transduced cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>Dosage and Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 100 × 106 iNKT Cohort 2 300 × 106 iNKT Cohort 3 1000 × 106 iNKT&#xD;
Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized patients as a single IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>agenT-797</intervention_name>
    <description>agenT-797 is an off-the shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex-vivo.</description>
    <arm_group_label>Dosage and Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily agree to participate and ability to provide informed consent or have duly&#xD;
             appointed health care proxy with the authority to consent.&#xD;
&#xD;
          2. ≥ 18 years of age.&#xD;
&#xD;
          3. Confirmed diagnosis of SARS-CoV-2 infection by polymerase chain reaction test or&#xD;
             equivalent approved test.&#xD;
&#xD;
          4. Inpatient hospitalization.&#xD;
&#xD;
          5. Evidence of SARS-CoV-2 infection with the diagnosis of moderate to severe ARDS per&#xD;
             Berlin definition (ARDS 2012), no more than 2 weeks prior to study enrollment.&#xD;
&#xD;
          6. Patients, or duly appointed health care proxy with the authority to consent, must&#xD;
             consent to placement of a central venous access line for the administration of&#xD;
             agenT-797.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently participating and receiving study therapy of an investigational agent that&#xD;
             is not registered for any other indication.&#xD;
&#xD;
             Note: Patients may receive the standard of care for SARS-CoV-2 infection as per&#xD;
             institutional practices.&#xD;
&#xD;
          2. Presence of comorbidities limiting expected survival of &lt; 1 month.&#xD;
&#xD;
          3. Any comorbidity which in the opinion of the Investigator may preclude/confound study&#xD;
             required safety and efficacy assessments.&#xD;
&#xD;
          4. Clinically significant cardiomyopathy.&#xD;
&#xD;
          5. Receipt of non-oncology vaccines containing live virus for prevention of infectious&#xD;
             diseases within 4 weeks prior to first dose of study treatment.&#xD;
&#xD;
          6. Known hypersensitivity to natural killer (NK) cells or their preservation solution.&#xD;
&#xD;
          7. Active systemic bacterial or fungal infection or viral co-infection.&#xD;
&#xD;
          8. Legally incapacitated or has limited legal capacity.&#xD;
&#xD;
          9. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Agenus Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agenus, Inc. Clinical Trial Information</last_name>
    <phone>781-674-4265</phone>
    <email>clinicaltrialinfo@agenusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine New York Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Van Besien, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <email>kov9001@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Koen Van Besien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

